News

Here are three strategies to navigate toward next-generation care management and increase member engagement in the process

Understanding the key barriers to biosimilar adoption in the U.S. is the first step managed care executives can take to overcome these obstacles, according to a Trinity Parners report.

Successfully separating the signal from the noise, especially in healthcare, can be a tremendous value creator.

Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.

FDA approved Allergan's supplemental New Drug Application (sNDA) to expand the approved use of ceftazidime and avibactam (Avycaz) to include 2 types of pneumonia.

FDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.

Putting together the right team of data specialists is an important part of the future growth of a healthcare organization. Do you have the right team in place?

Study reveals growing acceptance of value-based payments among family physicians, but barriers still exist.

In the next decade, many of the concepts aiming to streamline the healthcare industry could be reality.

Health systems realize that telehealth can help them achieve a wide range of objectives, from care coordination to readmission avoidance and market share expansion.

Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.

Corporate giants Amazon, Berkshire Hathaway, and JPMorgan Chase, partner to shake things up in U.S. employee healthcare.

FDA approved a new drug to treat a type of cancer that affects the pancreas or gastrointestinal tract.

Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.

A pharmaceutical formulation of purified cannabidiol, a cannabinoid without euphoric side effects, is expected to launch in the second half of this year.

A KPMG-Leavitt Partners report shows Medicare Advantage and Managed Medicaid are on slightly different trajectories. Expert Ash Shehata shares his predictions for both markets.

A Stanford expert describes ideal treatment locations, common barriers, and how payers could better support patients and families.

In partnership with the several big-name cancer centers, one company has commenced clinical trials. Find out how this cancer vaccine would work.

A University of Phoenix College of Health Professions survey has surprising findings about RNs and health administrator views on healthcare hacking.

A new report from Radware has shocking findings about the healthcare industry’s low preparedness levels for cyberthreats. Here’s 4 ways to get ready.

Reducing readmissions for chronic obstructive pulmonary disease (COPD) is an ongoing challenge for healthcare systems. Here’s how one is successful.

The flu epidemic is taking a toll on the U.S. healthcare system. Here's how health insurers can curtail spending on flu care.

The impact of VBRs on outcomes, VBRs versus other healthcare reimbursement initiatives, and VBR successes and failures. Pfizer’s Robert Popovian, PharmD, weighs in.

A patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.

From State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.

How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.